These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31514062)

  • 1. Recent advances in the development of cyclin-dependent kinase 7 inhibitors.
    Teng Y; Lu K; Zhang Q; Zhao L; Huang Y; Ingarra AM; Galons H; Li T; Cui S; Yu P; Oumata N
    Eur J Med Chem; 2019 Dec; 183():111641. PubMed ID: 31514062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
    Wang M; Wang T; Zhang X; Wu X; Jiang S
    Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
    Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
    Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
    Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
    Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
    Liang H; Du J; Elhassan RM; Hou X; Fang H
    Expert Opin Investig Drugs; 2021 Jan; 30(1):61-76. PubMed ID: 33183110
    [No Abstract]   [Full Text] [Related]  

  • 6. Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors.
    Zhang H; Lin G; Jia S; Wu J; Zhang Y; Tao Y; Huang W; Song M; Ding K; Ma D; Fan M
    Bioorg Chem; 2024 Jul; 148():107456. PubMed ID: 38761706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7).
    Ji W; Du G; Jiang J; Lu W; Mills CE; Yuan L; Jiang F; He Z; Bradshaw GA; Chung M; Jiang Z; Byun WS; Hinshaw SM; Zhang T; Gray NS
    Eur J Med Chem; 2024 Oct; 276():116613. PubMed ID: 39004018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
    Patel H; Periyasamy M; Sava GP; Bondke A; Slafer BW; Kroll SHB; Barbazanges M; Starkey R; Ottaviani S; Harrod A; Aboagye EO; Buluwela L; Fuchter MJ; Barrett AGM; Coombes RC; Ali S
    Mol Cancer Ther; 2018 Jun; 17(6):1156-1166. PubMed ID: 29545334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
    Sánchez-Martínez C; Lallena MJ; Sanfeliciano SG; de Dios A
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126637. PubMed ID: 31477350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
    Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
    Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.
    Kelso TW; Baumgart K; Eickhoff J; Albert T; Antrecht C; Lemcke S; Klebl B; Meisterernst M
    Mol Cell Biol; 2014 Oct; 34(19):3675-88. PubMed ID: 25047832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
    Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
    Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
    Diab S; Yu M; Wang S
    J Med Chem; 2020 Jul; 63(14):7458-7474. PubMed ID: 32150405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
    Zhong L; Yang S; Jia Y; Lei K
    J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
    Chow PM; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH
    Cancer Lett; 2021 Jun; 507():70-79. PubMed ID: 33741425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
    Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
    Kovalová M; Havlíček L; Djukic S; Škerlová J; Peřina M; Pospíšil T; Řezníčková E; Řezáčová P; Jorda R; Kryštof V
    Biomed Pharmacother; 2023 May; 161():114492. PubMed ID: 36931035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.
    Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7.
    Zhang H; Lin G; Jia S; Zhang Y; Wu J; Tao Y; Huang W; Song M; Ding K; Ma D; Fan M
    Eur J Med Chem; 2024 Jan; 263():115955. PubMed ID: 38000213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
    Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
    Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.